

FIRST LIGHT 13 January 2022

RESEARCH

BOB Economics Research | CPI and IIP

Inflation and industrial growth: horns of dilemma?

IT Services

Demand strong; Infosys shines

Technology & Internet

ISG Q4CY21 earnings call takeaways

SUMMARY

India Economics: CPI and IIP

CPI inflation came in as per our expectation of 5.6%. Unfavorable base came into play in pushing CPI higher. Even inflationary pressure was observed in major food categories such as cereals and products, milk, oils etc. Core was also sticky at 6.1%. Industrial production eased for the third consecutive month to 1.4% in Nov'21. Notably, IIP growth over a 2-year basis fell by 0.2%. Thus RBI is faced with the double whammy and likely to be on a wait and watch mode before taking any decision on rates.

Click here for the full report.

IT Services

- Infosys and TCS outperformed already optimistic revenue growth expectations;
 Wipro's 2.3% QoQ dollar revenue growth was a miss
- Companies reiterate strong demand and indicate broadly near-term profitability status-quo
- We revise up FY23EPS for TCS, INFO and Wipro by 1%/3%/0% respectively and reiterate BUY rating on all three

Click here for the full report.

Daily macro indicators

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%) India 10Y yield (%)	1.74	(2bps)	25bps	61bps
	6.57	(2bps)	20bps	65bps
USD/INR	73.91	0.2	2.5	(0.9)
Brent Crude (US\$/bbl)	83.72	3.5	11.4	48.0
Dow	36,252	0.5	0.8	16.7
Shanghai	3,567	(0.7)	(2.7)	(1.1)
Sensex	60,617	0.4	3.1	22.4
India FII (US\$ mn)	10-Jan	MTD	CYTD	FYTD
FII-D	(67.4)	(45.6)	(45.6)	456.6
FII-E	(19.6)	391.8	391.8	(3,173.4)

Source: Bloomberg

BOBCAPS Research researchreport@bobcaps.in





Technology & Internet

- Demand for IT services strong though significant headwinds also present in the form of high attrition and supply chain disruptions
- In CY21, BFSI saw significant traction among verticals and APAC among geographies
- ISG's CY22 guidance ascribes 20% YoY growth to the as-a-service market and just
 5.1% to managed services

Click here for the full report.

EQUITY RESEARCH 13 January 2022



CPI and **IIP**

12 January 2022

Inflation and industrial growth: horns of dilemma?

CPI inflation came in as per our expectation of 5.6%. Unfavorable base came into play in pushing CPI higher. Even inflationary pressure was observed in major food categories such as cereals and products, milk, oils etc. Core was also sticky at 6.1%. Industrial production eased for the third consecutive month to 1.4% in Nov'21. Notably, IIP growth over a 2-year basis fell by 0.2%. Thus RBI is faced with the double whammy and likely to be on a wait and watch mode before taking any decision on rates.

Madan Sabnavis Chief Economist

Authors

Dipanwita Mazumdar Economist

Sonal Badhan Economist

CPI inches up: Inflation for Dec'21 came in at 5.6% which was higher than that in Nov'21 when it was 4.9% and 4.5% in Oct'21. Unfavourable base (4.6% in Dec'20 against 6.9% in Nov'20) came into play in lifting CPI print higher. Inflation was higher than the country average in case of 9 items: oils and fats, non-alcoholic beverages, prepared meals and snacks, clothing and footwear, fuel and light, household goods and services, health, transport and communication and recreation and amusement categories. Core CPI (excl. food and fuel) was sticky at 6.1%. Even core excl. Pan & Tobacco, remained elevated at 6.3% in Dec'21 compared to 6.2% in Nov'21.

CPI to average at 5.2%: Inflation is sticky remaining above 5%. Even, price pressure is visible across major food categories. Core inflation is also a cause of worry and hence will be closely watched by RBI. We expect inflation to average 5.2% in FY22. While it is within the tolerance band of the MPC, it is definitely on the higher end and would ideally support the view that the repo rate needs to be hiked. However, the RBI has maintained that growth is priority and here the industrial production performance needs to be viewed in the light of the NSO projecting GDP growth at 9.2% against RBI's 9.5%.

IIP easing: Industrial output in Nov'21 eased for the third consecutive month to 1.4% from 4% in Oct'21. Slowdown was broad based with mining and manufacturing slowing the most. Within manufacturing, transport equipment and machinery production fell the most. Amongst the use-based classification, capital goods and consumer durables production contracted sharply in Nov'21.

Recovery in IIP hanging in balance: During Apr-Nov'21, IIP has risen by 17.4% compared with a decline of 15.3% in the same period over the previous year. However, a worrying trend emerged in Nov'21 as the IIP growth over a 2-year basis fell by 0.2% in Nov'21 compared with pre-pandemic levels. This trend was seen despite sharp improvement in domestic activity owing to festive and holiday season. One reason could be fewer working days and the other could be stocking of products by wholesalers well in advance. Going ahead, we expect some impact of Omicron on production as case load across the country rises and demand slows.





IT SERVICES

13 January 2022

Demand strong; Infosys shines

 Infosys and TCS outperformed already optimistic revenue growth expectations; Wipro's 2.3% QoQ dollar revenue growth was a miss

Companies reiterate strong demand and indicate broadly near-term profitability status-quo

 We revise up FY23EPS for TCS, INFO and Wipro by 1%/3%/0% respectively and reiterate BUY rating on all three Ruchi Burde | Seema Nayak researchreport@bobcaps.in

On a roll: Looking at the top-3 results, demand environment looks robust and management commentary is confident. Deal pipeline remains strong, driven by cloud, life-sciences and manufacturing verticals in particular. Europe demand remains high across the board. The deal pipeline has a greater number of small and mid-sized deals. Attrition has gone up across the board, which has kept the margins flattish despite growth outperformance. However, all three companies hinted at attrition starting to stabilize.

TCS delivered sanguine results: TCS reported QoQ USD growth of 3%, exceeding our estimate of 2%. The growth was broad based across verticals with growth for most between 2-4 % QoQ USD. Geography wise India grew the most at 11% QoQ USD. EBIT margin stood at 25%, roughly in-line with our estimates of 25.3%. TCV stood at USD7.6 bn, flat QoQ. Attrition jumped to 15.3%, up 340bps QoQ. TCS hired ~28000 employees in Q3.

Infosys sprints ahead: Infosys reported 6.3% QoQ USD revenue, exceeding our (2.9%) and street's estimate by a distance. TCV at USD 2.53bn was up 17.7% QoQ USD. The growth was broad-based led by 'others' segment, life-sciences and manufacturing which were up by 28.4%/12.3%/ 10.2%, QoQ USD. BFSI was up by a muted 3.7%. The impressive performance led to a major FY22 growth guidance upgrade from 16.5-17.5% CC to 19.5%-20%. EBIT margin at 23.5% was flattish QoQ. The only major dampener was attrition soaring to 25.5%, up 540bps QoQ.

Wipro underperformed: Wipro underperformed our estimate of 3.3% growth with a QoQ USD growth of 2.3%. The growth was broad-based with retail and BFSI driving the momentum with 4.7% and 3.5% growth. EBIT margin at 17.6% was below our estimate of 18.1%. However, the Q4FY22 revenue growth guidance of 2-4% QoQ CC, was in line with our estimates, translating into FY22 growth of 27-28%. Pipeline is strong with a mix of small and mid-sized deals. We adjust TCS FY23/24 EPS by 1%/1%, INFO'S by 3%/3%. WPRO's by -0.1%/0%, factoring in the results. We keep the target multiples intact for all (TCS/INFY/WPRO:36.5x/34x/29x). Maintain BUY

Recommendation snapshot

Ticker	Price	Target	Rating
INFO IN	1,877	2,250	BUY
TCS IN	3,860	4,770	BUY
WPRO IN	691	850	BUY

Price & Target in Rupees | Price as of 12 Jan 2022





TECHNOLOGY & INTERNET

ISG Q4CY21 earnings call takeaways

- Demand for IT services strong though significant headwinds also present in the form of high attrition and supply chain disruptions
- In CY21, BFSI saw significant traction among verticals and APAC among geographies
- ISG's CY22 guidance ascribes 20% YoY growth to the as-a-service market and just 5.1% to managed services

Robust demand: ISG's conference call today focused on global trends emerging in the IT industry, including tailwinds such as strong demand, a robust deal pipeline and increased M&A traction, as well as headwinds of wage inflation, the great resignation, supply chain disruptions and Covid impact. Record-high ACV was seen in managed services (US\$ 8.6bn) and as-a-service (US\$ 14bn) in CY21. Combined market ACV stood at US\$ 23bn, up 30% YoY. The emergence of small and midsized deals is another key trend, resulting from enterprises moving toward fast-paced transformation.

Attrition to persist: ISG estimates that attrition will persist in the near-to-mid-term but should normalise within the next couple of quarters. Currently, the industry average attrition rate is over 20%. Wage inflation has occurred because of this high churn. Both managed services and T&M (time & material) are seeing wage inflation. In managed services, rates are steady for existing contracts while in T&M, rates have risen 4-7% for in-demand skills. Providers are recruiting more freshers and ramping up training. Mass hiring and subcontracting have also increased.

BFSI leads among verticals: BFSI demand remains robust in both managed services and as-a-service segments. The combined market ACV for BFSI rose 30% in CY21 while as-a-service grew 38%. Other verticals with high combined market ACV growth are travel & hospitality and retail, CPG & manufacturing, up 36% and 38% respectively. APAC's combined market ACV grew the most among geographies at 44% YoY. America grew by 27%, followed by EMEA at 23%. The DACH region was affected by supply chain disruptions whereas Eastern Europe saw record high ACV.

Strong outlook for as-a-service market: ISG has guided for 20% YoY growth for the as-a-service market in CY22. It expects managed services to grow 5.1% which looks subdued and is below the CY21 estimate (+10.1% YoY in Q3CY21). However, this is still 2.5x the historical industry average growth rate over CY10-CY20.

Emerging trends in manufacturing: The top 5 trends on C-level agendas are IoT and cybersecurity, ESG, monetisation of software and services, M&A for new skills and capabilities, and building a future-ready supply chain.

12 January 2022

Ruchi Burde | Seema Nayak researchreport@bobcaps.in

Recommendation snapshot

Ticker	Price	Target	Rating	
COFORGE IN	5,767	7,040	BUY	
ECLX IN	2,833	3,690	BUY	
HCLT IN	1,344	1,560	BUY	
INFO IN	1,856	2,170	BUY	
LTI IN	7,174	8,270	BUY	
MPHL IN	3,207	3,650	HOLD	
MTCL IN	4,584	3,540	SELL	
PSYS IN	4,492	4,240	HOLD	
TCS IN	3,916	4,720	BUY	
TECHM IN	1,737	1,970	BUY	
WPRO IN	694	850	BUY	

Price & Target in Rupees | Price as of 11 Jan 2022





Disclaimer

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above

Rating distribution

As of 31 December 2021, out of 115 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 57 have BUY ratings, 31 have HOLD ratings, 5 are rated ADD*, 2 are rated REDUCE* and 20 are rated SELL. None of these companies have been investment banking clients in the last 12 months. (*Our ADD and REDUCE ratings are in the process of being migrated to the new recommendation structure.)

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2025. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017. BOBCAPS CIN Number: U65999MH1996G01098009.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed

EQUITY RESEARCH 13 January 2022

FIRST LIGHT



in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

EQUITY RESEARCH 13 January 2022